Paper Details

  1. Home
  2. Paper Details

Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial.

Author: , AilawadhiSikander, CallanderNatalie, DhodapkarMadhav, DurieBrian, HitaSandi Fredette, HoeringAntje, LipeBrea, OrlowskiRobert Z, RajkumarS Vincent, RichardsonPaul G, RosenzweigMichael, SextonRachael, UsmaniSaad Z, ValentJason, VoorheesPeter M, ZimmermanTodd, ZonderJeffrey A

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

New treatments have improved outcomes for multiple myeloma, a type of blood cancer. However, patients with high-risk disease have a poor long-term outlook. This study aims to find the best treatment for these patients.
Paper Details　
Original Abstract of the Article :
The introduction of immunomodulatory agents, proteasome inhibitors, and autologous haematopoietic stem-cell transplantation has improved outcomes for patients with multiple myeloma, but patients with high-risk multiple myeloma have a poor long-term prognosis. We aimed to address optimal treatment fo...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/33357482

データ提供：米国国立医学図書館（NLM）

Attacking Multiple Myeloma: A New Treatment Regimen Shows Promise

Multiple myeloma, a type of blood cancer that affects plasma cells, can be a challenging condition to treat. This study investigates the effectiveness of a new treatment regimen for patients with untreated, high-risk multiple myeloma. The researchers conducted a randomized, phase 2 trial comparing a combination of bortezomib, lenalidomide, dexamethasone, and elotuzumab to the same regimen without elotuzumab. The results are expected to shed light on the potential benefits of adding elotuzumab to this treatment regimen.

A New Frontier in Multiple Myeloma Treatment

This study offers valuable insights into the potential of a novel treatment regimen for patients with high-risk multiple myeloma. The researchers are investigating the efficacy of adding elotuzumab to a combination of bortezomib, lenalidomide, and dexamethasone. The findings could lead to improved treatment outcomes and a better prognosis for patients with this challenging condition.

Hope for Multiple Myeloma Patients: A New Treatment Approach

Multiple myeloma can be a debilitating disease, but this research offers a glimmer of hope for patients with high-risk disease. The researchers are exploring a new treatment regimen that could potentially improve outcomes and enhance the quality of life for these patients.

Dr. Camel's Conclusion

This study investigates a new treatment regimen for patients with untreated, high-risk multiple myeloma. The researchers are comparing a combination of bortezomib, lenalidomide, dexamethasone, and elotuzumab to the same regimen without elotuzumab. The findings could lead to improved treatment outcomes and a better prognosis for patients with this challenging condition.

Date :
  1. Date Completed 2021-01-04
  2. Date Revised 2021-11-20
Further Info :

Pubmed ID

33357482

DOI: Digital Object Identifier

NIHMS1753545

Related Literature

Article Analysis
・Effective treatment of multiple myeloma
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.